Outcomes of early versus late radiotherapy in grade 2 meningiomas: a National retrospective analysis from the TROD neuro-oncology group - Takeaways - MDSpire

Outcomes of early versus late radiotherapy in grade 2 meningiomas: a National retrospective analysis from the TROD neuro-oncology group

  • By

  • Volkan Demircan

  • Ertuğrul Şentürk

  • Evrim Tezcanlı

  • Petek Erpolat

  • Züleyha Akgün

  • Serra Kamer

  • Necla Gürdal

  • Beyhan Ceylaner Bıçakçı

  • Burak Erdemci

  • Nuri Kaydıhan

  • Banu Atalar

  • May 5, 2026

  • 0 min

Share

  • 1

    Grade 2 meningiomas, comprising 4-5% of cases, have seen increased incidence rates due to evolving WHO classifications and diagnostic criteria.

  • 2

    Adjuvant radiotherapy (RT) is recommended after subtotal resection for grade 2 meningiomas, but its role post-gross total resection remains uncertain.

  • 3

    Historical data indicate that 3-year progression-free survival rates improve from 70% with gross total resection alone to nearly 90% with adjuvant RT.

  • 4

    This multicenter study aims to evaluate the impact of RT timing on long-term outcomes for patients with grade 2 meningiomas across Turkey.

  • 5

    Patients were categorized into early and late RT groups based on the timing of treatment initiation relative to disease progression.

Original Source(s)

Outcomes of early versus late radiotherapy in grade 2 meningiomas: a National retrospective analysis from the TROD neuro-oncology group

  • by Volkan Demircan, Ertuğrul Şentürk, Evrim Tezcanlı, Petek Erpolat, Züleyha Akgün, Serra Kamer, Necla Gürdal, Beyhan Ceylaner Bıçakçı, Burak Erdemci, Nuri Kaydıhan, Banu Atalar

  • May 5, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment